These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 11371699)

  • 21. Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort.
    Calmy A; Pinoges L; Szumilin E; Zachariah R; Ford N; Ferradini L;
    AIDS; 2006 May; 20(8):1163-9. PubMed ID: 16691068
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).
    Squires KE; Gulick R; Tebas P; Santana J; Mulanovich V; Clark R; Yangco B; Marlowe SI; Wright D; Cohen C; Cooley T; Mauney J; Uffelman K; Schoellkopf N; Grosso R; Stevens M
    AIDS; 2000 Jul; 14(11):1591-600. PubMed ID: 10983646
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stavudine but not didanosine as part of HAART contributes to peripheral lipoatrophy: a substudy from the Antiretroviral Regimen Evaluation Study (ARES).
    Lowe SH; Hassink EA; van Eck-Smit BL; Borleffs JC; Lange JM; Reiss P
    HIV Clin Trials; 2007; 8(5):337-44. PubMed ID: 17956835
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Baseline CD4 cell counts and outcomes among adult treatment naive HIV patients after taking fixed dose combination GPO-VIR-S and GPO-VIR-Z in Thailand.
    Kyaw NL; Thanachartwet V; Kiertiburanakul S; Desakorn V; Chamnanchanunt S; Chierakul W; Manosuthi W; Pitisuttithum P; Sungkanuparph S
    Southeast Asian J Trop Med Public Health; 2013 Mar; 44(2):232-43. PubMed ID: 23691633
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1.
    Krogstad P; Lee S; Johnson G; Stanley K; McNamara J; Moye J; Jackson JB; Aguayo R; Dieudonne A; Khoury M; Mendez H; Nachman S; Wiznia A;
    Clin Infect Dis; 2002 Apr; 34(7):991-1001. PubMed ID: 11880966
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unrecognized near-fatal hyperlactatemia in an HIV-infected infant exposed to nucleoside reverse transcriptase inhibitors.
    Koh MT
    Int J Infect Dis; 2007 Jan; 11(1):85-6. PubMed ID: 16581278
    [No Abstract]   [Full Text] [Related]  

  • 27. A pilot study of nevirapine, indinavir, and lamivudine among patients with advanced human immunodeficiency virus disease who have had failure of combination nucleoside therapy.
    Harris M; Durakovic C; Rae S; Raboud J; Fransen S; Shillington A; Conway B; Montaner JS
    J Infect Dis; 1998 Jun; 177(6):1514-20. PubMed ID: 9607828
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term efficacy of a protease inhibitor-sparing, nucleoside reverse transcriptase inhibitor-limiting antiretroviral regimen with nevirapine, lamivudine, and reduced standard stavudine dosage.
    Shalit P; Farrell P; McClarty M
    HIV Clin Trials; 2004; 5(1):62-4. PubMed ID: 15002088
    [No Abstract]   [Full Text] [Related]  

  • 29. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).
    Eron JJ; Murphy RL; Peterson D; Pottage J; Parenti DM; Jemsek J; Swindells S; Sepulveda G; Bellos N; Rashbaum BC; Esinhart J; Schoellkopf N; Grosso R; Stevens M
    AIDS; 2000 Jul; 14(11):1601-10. PubMed ID: 10983647
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Toxic epidermal necrolysis associated with abacavir].
    Montero M; García-Gibert L; Giménez-Arnau AM; Knobel H
    Enferm Infecc Microbiol Clin; 2005 Apr; 23(4):247. PubMed ID: 15826554
    [No Abstract]   [Full Text] [Related]  

  • 31. Clinical experience with nevirapine combined with tenofovir plus emtricitabine or lamivudine-containing regimens in HIV-infected subjects.
    Smith DE; Chan DJ; Maruszak H; Jeganathan S
    Int J STD AIDS; 2011 Apr; 22(4):228-30. PubMed ID: 21515757
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lactic acid levels in children perinatally treated with antiretroviral agents to prevent HIV transmission.
    Giaquinto C; De Romeo A; Giacomet V; Rampon O; Ruga E; Burlina A; De Rossi A; Sturkenboom M; D'Elia R
    AIDS; 2001 May; 15(8):1074-5. PubMed ID: 11399997
    [No Abstract]   [Full Text] [Related]  

  • 33. [Reliable effectiveness for years with good long-term tolerance: 10 years nevirapine--a summary].
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():70. PubMed ID: 19024921
    [No Abstract]   [Full Text] [Related]  

  • 34. Lipodystrophy associated with nevirapine-containing antiretroviral therapies.
    Aldeen T; Wells C; Hay P; Davidson F; Lau R
    AIDS; 1999 May; 13(7):865-7. PubMed ID: 10357391
    [No Abstract]   [Full Text] [Related]  

  • 35. Higher rate of toxicity with no increased efficacy when hydroxyurea is added to a regimen of stavudine plus didanosine and nevirapine in primary HIV infection.
    Zala C; Salomon H; Ochoa C; Kijak G; Federico A; Perez H; Montaner JS; Cahn P
    J Acquir Immune Defic Syndr; 2002 Apr; 29(4):368-73. PubMed ID: 11917241
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [A fixed dose anti-HIV combination for the poor? Triomune].
    Garcia MV; Mukeba-Tshialala D; Vaira D; Moutschen M
    Rev Med Liege; 2009 Jan; 64(1):32-6. PubMed ID: 19317099
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Demographic, socio-economic, behavioral and clinical factors predicting virologic failure with generic fixed-dose combination antiretroviral therapy before universal health insurance coverage in northern Thailand.
    Tsuchiya N; Pathipvanich P; Yasuda T; Mukoyama Y; Rojanawiwat A; Matsubayashi T; Saeng-aroon S; Auwanit W; Matsuyama A; Sawanpanyalert P; Ariyoshi K
    Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):71-82. PubMed ID: 19323037
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tenofovir resistance among HIV-infected patients failing a fixed-dose combination of stavudine, lamivudine, and nevirapine in a resource-limited setting.
    Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Chantratitra W
    AIDS Patient Care STDS; 2007 Oct; 21(10):711-4. PubMed ID: 17949267
    [No Abstract]   [Full Text] [Related]  

  • 39. Mitigation of hepato-cellular injury caused by HAART with glycyrrhizin compound in patients co-infected with HIV and HCV.
    Yamamoto Y; Yasuoka A; Tachikawa N; Teruya K; Genka I; Yamaguchi M; Yasuoka C; Kikuchi Y; Aoki M; Oka S
    Jpn J Infect Dis; 1999 Dec; 52(6):248-9. PubMed ID: 10738365
    [No Abstract]   [Full Text] [Related]  

  • 40. [Efficacy and safety of the substitution of zidovudine by nevirapine in treatments based on three nucleoside analogue reverse transcriptase inhibitors in HIV-1 infected patients].
    Tasias M; Ruiz S; Deig E; Pedrol E
    Enferm Infecc Microbiol Clin; 2011; 29(7):556-7. PubMed ID: 21565428
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.